Simcere Pharmaceutical Group Ltd.
Chinese specialty pharmaceutical company developing and commercialising innovative drugs for neur…
Chinese specialty pharmaceutical company developing and commercialising innovative drugs for neurological, oncological, and auto-immune diseases, with a growing consumer health portfolio of neurology-adjacent OTC and functional health products. Listed on the Hong Kong Stock Exchange with a pipeline of novel small-molecule and biologic drugs.
- Type
- Manufacturer
- Location
- Nanjing, China
- Founded
- 1995
- Website
- simcere.com
- Categories
- Medical & Healthcare Supplies, Supplements & Wellness
- Markets
- China, United States, Germany, Japan, Hong Kong
Verified facts
- corporate-mail-on-domain (green), checked 2026-08-09 Mail server of the company domain
- domain-registered (green), checked 2026-08-09 Domain registry record
- sanctions-clear (green), checked 2026-08-09 OpenSanctions
- debarment-clear (green), checked 2026-08-09 OpenSanctions
Claimed certifications
- ISO 9001, Quality Management IAF CertSearch
- Good Manufacturing Practice
- ISO 14001, Environmental Management IAF CertSearch
Import rules for these goods
- Food supplements sold in the EU follow Directive 2002/46/EC: most member states require a notification to the national authority before the first sale. European Commission (supplements)
- Medical devices sold in the EU must carry CE marking under the Medical Device Regulation (EU) 2017/745, with a conformity assessment matched to the device risk class. European Commission (MDR)
- For the US market, the maker must have an FDA device establishment registration and product listing; most instruments also need 510(k) premarket clearance. US FDA (devices)